Side-by-side comparison of AI visibility scores, market position, and capabilities
Global #1 OTC acetaminophen brand owned by Kenvue (NYSE: KVUE, J&J 2023 spinoff at $41B); Kimberly-Clark $48.7B Kenvue acquisition pending close H2 2026 competing with Advil and store brand for OTC pain relief market.
Tylenol is a global over-the-counter acetaminophen (paracetamol) pain relief and fever reducer brand — owned by Kenvue (NYSE: KVUE), the consumer health company spun off from Johnson & Johnson in May 2023 at a $41 billion IPO valuation, and subject to a pending $48.7 billion acquisition by Kimberly-Clark announced in November 2025 (expected to close second half 2026) — providing consumers with the world's most widely used analgesic through product lines including Tylenol Extra Strength, Tylenol PM, Tylenol Rapid Release Gels, Tylenol Children's, and Tylenol Arthritis Pain for adults and pediatric pain and fever management. Generating approximately $2 billion in annual retail sales as one of Kenvue's flagship brands alongside Neutrogena, Band-Aid, Listerine, and Zyrtec, Tylenol is the #1 recommended pain reliever by doctors and pharmacists in the United States. Originally marketed by McNeil Laboratories (acquired by J&J in 1959), the brand was approved for OTC sale in 1960.
Synaptive Medical raised $260M total; secured new strategic investment in Jul 2025 to accelerate growth; BrightMatter robotic imaging suite enhances neurosurgical precision with 3D tractography navigation.
Synaptive Medical is a Toronto-based medical device company founded in 2012 that develops integrated surgical robotics, imaging, and navigation solutions for neurosurgery. Its flagship product line — the BrightMatter suite — includes BrightMatter Prime (pre-operative planning with high-fidelity imaging), BrightMatter Guide (FDA-cleared 3D neuronavigation with tractography), and BrightMatter Servo (robotic microscope positioning with hands-free alignment and real-time 3D tractography visualization in the OR).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.